Literature DB >> 23809693

Analysis of high-dose rate brachytherapy dose distribution resemblance in CyberKnife hypofractionated treatment plans of localized prostate cancer.

H Sudahar1, P G G Kurup, V Murali, P Mahadev, J Velmurugan.   

Abstract

The present study is to analyze the CyberKnife hypofractionated dose distribution of localized prostate cancer in terms of high-dose rate (HDR) brachytherapy equivalent doses to assess the degree of HDR brachytherapy resemblance of CyberKnife dose distribution. Thirteen randomly selected localized prostate cancer cases treated using CyberKnife with a dose regimen of 36.25Gy in 5 fractions were considered. HDR equivalent doses were calculated for 30Gy in 3 fractions of HDR brachytherapy regimen. The D5% of the target in the CyberKnife hypofractionation was 41.57 ± 2.41Gy. The corresponding HDR fractionation (3 fractions) equivalent dose was 32.81 ± 1.86Gy. The mean HDR fractionation equivalent dose, D98%, was 27.93 ± 0.84Gy. The V100% of the prostate target was 95.57% ± 3.47%. The V100% of the bladder and the rectum were 717.16 and 79.6mm(3), respectively. Analysis of the HDR equivalent dose of CyberKnife dose distribution indicates a comparable resemblance to HDR dose distribution in the peripheral target doses (D98% to D80%) reported in the literature. However, there is a substantial difference observed in the core high-dose regions especially in D10% and D5%. The dose fall-off within the OAR is also superior in reported HDR dose distribution than the HDR equivalent doses of CyberKnife. Crown
Copyright © 2013 Published by Elsevier Inc. on behalf of American Association of Medical Dosimetrists.

Entities:  

Keywords:  CyberKnife; HDR brachytherapy; Hypofractionation; Localized prostate

Mesh:

Year:  2013        PMID: 23809693     DOI: 10.1016/j.meddos.2013.04.006

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  5 in total

1.  Salvage image-guided intensity modulated or stereotactic body reirradiation of local recurrence of prostate cancer.

Authors:  D Zerini; B A Jereczek-Fossa; C Fodor; F Bazzani; A Maucieri; S Ronchi; S Ferrario; S P Colangione; M A Gerardi; M Caputo; A Cecconi; F Gherardi; A Vavassori; S Comi; R Cambria; C Garibaldi; F Cattani; O De Cobelli; R Orecchia
Journal:  Br J Radiol       Date:  2015-06-09       Impact factor: 3.039

2.  Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.

Authors:  Michael Wahl; Martina Descovich; Erin Shugard; Dilini Pinnaduwage; Atchar Sudhyadhom; Albert Chang; Mack Roach; Alexander Gottschalk; Josephine Chen
Journal:  Technol Cancer Res Treat       Date:  2016-07-08

3.  Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.

Authors:  Aurélie Mbeutcha; Laurent Chauveinc; Pierre-Yves Bondiau; Marie-Eve Chand; Matthieu Durand; Daniel Chevallier; Jean Amiel; Daniel Lam Cham Kee; Jean-Michel Hannoun-Lévi
Journal:  Radiat Oncol       Date:  2017-03-09       Impact factor: 3.481

Review 4.  High-dose-rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome.

Authors:  Iosif Strouthos; Efstratios Karagiannis; Nikolaos Zamboglou; Konstantinos Ferentinos
Journal:  Cancer Rep (Hoboken)       Date:  2021-06-23

Review 5.  The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry.

Authors:  Tibor Major; Georgina Fröhlich; Péter Ágoston; Csaba Polgár; Zoltán Takácsi-Nagy
Journal:  Strahlenther Onkol       Date:  2021-11-01       Impact factor: 3.621

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.